Novavax (NVAX) vs. Synageva Biopharma (GEVA) Head to Head Comparison
Novavax (NASDAQ: NVAX) and Synageva Biopharma (NASDAQ:GEVA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.
Institutional and Insider Ownership
36.8% of Novavax shares are held by institutional investors. 4.0% of Novavax shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This table compares Novavax and Synageva Biopharma’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Novavax||$15.35 million||28.81||-$279.96 million||($0.68)||-2.07|
Synageva Biopharma has lower revenue, but higher earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Synageva Biopharma, indicating that it is currently the more affordable of the two stocks.
This table compares Novavax and Synageva Biopharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings and recommmendations for Novavax and Synageva Biopharma, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Novavax presently has a consensus price target of $3.43, indicating a potential upside of 148.79%.
Novavax beats Synageva Biopharma on 6 of the 8 factors compared between the two stocks.
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company’s product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company’s lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).
About Synageva Biopharma
Synageva BioPharma Corp. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for the treatment of rare diseases. The Company has a pipeline of protein therapeutic programs for rare diseases. Its lead product is Kanuma (sebelipase alfa) being developed for the treatment of lysosomal acid lipase deficiency (LAL Deficiency). The Company’s other product candidates under development include SBC-103, a first-mover enzyme replacement therapy program for mucopolysaccharidosis IIIB (MPS IIIB, also known as Sanfilippo B syndrome) and SBC-105, which is a first-mover enzyme therapy in preclinical development for rare disorders of calcification, including the indication generalized calcification in infants (GACI). The Company also has additional first-mover and potentially bio-superior protein therapeutic pipeline programs for other rare diseases at different stages of preclinical development.
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.